A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

A Prospective, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Adaptive Phase 3 Study With Open-label Extension to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04271475

Acronym

MACiTEPH

Enrollment

127

Registered

2020-02-17

Start date

2020-07-07

Completion date

2023-12-21

Last updated

2025-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Thromboembolic Pulmonary Hypertension

Brief summary

The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).

Detailed description

CTEPH is one of the leading causes of severe pulmonary hypertension (PH), classified within World Health Organization (WHO) group 4 PH. It is a rare, progressive pulmonary vascular disease that if left untreated, leads to progressively increasing pulmonary vascular resistance (PVR) and eventually right ventricle failure and death. Histopathologic findings including endothelial cell dysfunction and distal pulmonary arterial remodeling are shared between PAH and CTEPH, and PH-specific therapies (that is, riociguat) have shown efficacy in inoperable and persistent/recurrent CTEPH. The endothelin receptor antagonist macitentan offers a different mode of action and addresses an important unmet medical need for an alternative treatment option in this indication. This study will assess the effect of macitentan 75 mg on exercise capacity in CTEPH. The total duration of the study is approximately 6 years. The study comprises of a screening period (at least 14 days and up to 60 days), a double-blind (DB) treatment period (28 weeks \[minimum duration\] up to 3.5 years), an open-label (OL) extension period (starts at end-of-DB-treatment \[EODBT\] and will end for all participants 104 weeks after the last participant has completed DB Week 28). The DB period consists of an 8-week up-titration phase and a maintenance phase. The maintenance phase is divided into a 28-week fixed duration part, at the end of which primary endpoint is assessed, and a variable duration part. The duration of the DB period for an individual participant depends on the timepoint of entry into the study and whether a CEC-confirmed clinical worsening event occurred. Participants who discontinue DB study intervention during the 28-week fixed duration part will be followed until Week 28 in a post-treatment observation period (PTOP).

Interventions

DRUGMacitentan

Participants will receive Macitentan film-coated tablets orally od.

DRUGPlacebo

Participant will receive matching placebo tablets orally od.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Chronic thromboembolic pulmonary hypertension (CTEPH) (World Health Organization \[WHO\] Group 4) fulfilling one of the following criteria: a) inoperable due to the localization of the obstruction being surgically inaccessible (that is, distal disease), b) persistent/recurrent CTEPH after balloon pulmonary angioplasty (BPA), and deemed inoperable due to the localization of the obstruction being surgically inaccessible (that is, distal disease), c) persistent/recurrent CTEPH after rescue pulmonary endarterectomy (PEA) * 6-minute walk distance (6MWD) greater than or equal to (\>=) 100 meter (m) and less than or equal to (\<=) 450 meters (m), documented by an eligibility and a baseline 6-minute walk test (6MWT). The baseline 6MWD must not differ by more than 15 percent (%) from the eligibility test * World Health Organization functional class (WHO FC) \>= II * Participants are to receive riociguat as per local standard of care, unless it is contraindicated or unavailable

Exclusion criteria

* Acute pulmonary embolism within 3 months prior to or during Screening * Planned balloon pulmonary angioplasty (BPA) during the fixed duration part of the double-blind period * Significant obstructive and restrictive lung disease * Acute or chronic conditions (other than dyspnea) that limit the ability to comply with study requirements, in particular with 6MWT (for example, intermittent claudication). * Symptomatic coronary artery disease requiring an intervention within 3 months prior to or during Screening or anticipated during the fixed duration part of the study * Decompensated cardiac failure if not under close supervision * Known and documented life-threatening cardiac arrhythmias * Acute myocardial infarction within 6 months prior to, or during Screening * Cerebrovascular events (including transient ischemic attack) within 3 months prior to, or during Screening * Known or suspicion of pulmonary veno-occlusive disease (PVOD) * Administration of ERAs, intravenous prostacyclins / prostacyclin analogs, or investigational treatment within 90 days prior to Randomization * Change in dose or initiation of Phosphodiesterase type-5 (PDE-5) inhibitors, oral, inhaled or subcutaneous (SC) prostacyclins / prostacyclin analogues, prostacyclin receptor agonists or riociguat, a) within 90 days prior to Randomization, or b) anticipated during the fixed duration part of the double-blind \[DB\] period * Hypotension, that is, systolic blood pressure (SBP) less than (\<) 90 millimeters of mercury (mmHg) or diastolic blood pressure (DBP) \<50 mmHg at Screening. * Severe renal dysfunction with an estimated Glomerular Filtration Rate \<30 milliliters per minute per 1.73 meter square (mL/min/1.73 m\^2) using the Chronic Kidney Disease Epidemiology Collaboration formula at Screening * Known moderate to severe hepatic impairment, defined as Child-Pugh Class B or C, based on records that confirm documented medical history * Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) greater than or equal to (\>=) 1.5\*upper limit of normal (ULN) at Screening * Hemoglobin \<100 g/L (\<10 gram per deciliter \[g/dL\]) at Screening

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in 6-minute Walk Distance (6MWD) at Week 28	Baseline (Day 1), Week 28	Change from baseline in 6MWD as measured by 6-minute walk test (6MWT) at Week 28 was reported. The purpose of the 6MWT was to quantify exercise tolerance and capacity. This standardized test measured the distance an individual was able to walk over a total of six minutes on a hard, flat surface with no obstacles. The goal was for the individual to walk as far as possible in 6 minutes.

Secondary

Measure	Time frame	Description
Number of Participants With Improvement in World Health Organization Functional Class (WHO FC) From Baseline to Week 28	From Baseline (Day 1) up to Week 28	Number of participants with improvement in WHO FC from baseline to Week 28 were reported. Improvement (decrease) in WHO FC from baseline to Week 28 was calculated for each participant. WHO FC test was used to assess disease severity. Four functional classes (FC) were defined from FC I (no limitation of physical activity) to FC IV (inability to carry out any physical activity without symptoms). For the analysis purpose, these WHO FC class values were transformed to a scale with scores ranged from 1 to 4; where a score of 1 corresponded to WHO FC Class I and a score of 4 corresponded to WHO FC Class IV. The higher scores indicate greater symptom severity or worse impact. Improvement was considered when a participant changed from a higher class to a lower class.
Change From Baseline to Week 28 in Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT) - Cardiopulmonary Symptom Domain Score	From Baseline (Day 1) up to Week 28	The cardiopulmonary symptoms domain consisted of 6 items: shortness of breath, fatigue, lack of energy, swelling in ankles or legs, swelling in stomach area and cough and were reported on a 5-point Likert scale from 0 (no symptom at all) to 4 (very severe symptoms), with higher score indicating more symptom. The symptoms part of the PAH-SYMPACT was administered daily over a 7-day period. The recall period of symptom items was the last 24 hours. The mean individual symptom item score was determined for each of the 6 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items, ranged from 0=no cardiopulmonary symptoms to 4=severe cardiopulmonary symptoms. A higher score indicated more severe symptoms experienced.
Time to First Clinical Event Committee (CEC) Confirmed Clinical Worsening up to End-of Double-blind-treatment (EODBT) Period	From Baseline (Day 1) up to EODBT: median 24.5 weeks (min 3.9 weeks; max 160.4 weeks) for macitentan, median 44 weeks (min 4 weeks; max 147.9 weeks) for placebo	Time (months) to first CEC-confirmed clinical worsening up to EODBT were reported. Clinical worsening was defined as the occurrence of at least one of the following events: 1) All-cause death; 2) Heart and/or lung transplantation; 3) Unplanned pulmonary hypertension (PH)-related hospitalization; 4) PH-related deterioration from baseline identified by at least one of the following: a) Persistent increase in World Health Organization functional class (WHO FC) that could not be explained by another cause (for example, viral infection); b) Persistent deterioration by at least 15 percent (%) in exercise capacity; as measured by the 6MWD; c) New or worsened signs or symptoms of right heart failure; 5) Rescue pulmonary endarterectomy (PEA) and/or balloon pulmonary angioplasty (BPA) procedure due to worsening of PH.
Change From Baseline to Week 28 in Euro Quality of Life-5-Dimension-5-Level (EQ-5D-5L) Utility Score and Visual Analog Scale (VAS) Score	From Baseline (Day 1) up to Week 28	The EQ-5D-5L was a generic measure of health status. The EQ-5D-5L consisted of 2 parts: EQ-5D-5L utility score (descriptive system) and VAS score. EQ-5D-5L descriptive system consisted of 5-item questionnaire that assessed 5 domains including mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each questionnaire had 5 response levels: 1 =no problems, 2 =slight problems, 3 =moderate problems, 4 =severe problems and 5 =extreme problems. The scores for the 5 questionnaires were used to compute a single utility score which ranged from 0 to 1, where higher score indicated better health state and lower score indicated worse health state. EQ-5D-5L VAS rated current health state on a vertical scale with a score ranged from 0 (worst imaginable health state) to 100 (best imaginable health state), higher scores indicated a better health state.
Change From Baseline to Week 28 in Accelerometer-assessed Proportion of Time Spent in Moderate to Vigorous Physical Activity	From Baseline (Day 1) up to Week 28	Change from baseline to Week 28 in accelerometer-assessed proportion of time spent in moderate to vigorous physical activity were assessed. Daily life physical activity of participant was assessed using accelerometer which was provided to the participant at screening and was worn daily during waking hours up to Week 28. For each scheduled visit, the 14 days prior to the visit were considered as the assessment period for physical activity. To be considered evaluable for a given timepoint, actigraphy variables should have been measured for at least 7 complete days (consecutive or not). A complete day is defined as a record of at least 7 waking hours of data. Proportion of time spent in moderate to vigorous physical activity was the estimated number of minutes spent in moderate or higher physical activity as calculated using the Staudenmayer '15 technique as proportion of the total minutes of algorithmically detected wear time and excluding the minutes that fall within a sleep period.
Change From Baseline to Week 28 in PAH-SYMPACT - Cardiovascular Symptom Domain Score	From Baseline (Day 1) up to Week 28	The cardiovascular symptoms domain consisted of 5 items: heart palpitations (fluttering), rapid heartbeat, chest pain, chest tightness, and lightheadedness and were reported on a 5-point Likert scale ranged from 0 (no symptoms at al) to 4 (very severe symptoms), with high score indicating more symptom. The symptoms part of PAH-SYMPACT was administered daily over a 7-day period. The recall period of symptom items was the last 24 hours. An average Cardiovascular Symptoms domain score was determined based on the daily scores of the 5 items. The mean individual symptom item score was determined for each of the 5 items and a domain score was calculated by summing the mean individual symptom item scores and dividing by the number of items, ranged from 0=no cardiovascular symptoms to 4=severe cardiovascular symptoms. Higher score indicated more severe symptoms experienced.

Countries

Argentina, Australia, Austria, Bulgaria, Canada, China, Colombia, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Japan, Lithuania, Mexico, Poland, Portugal, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, South Korea, Spain, Taiwan, Thailand, Turkey (Türkiye), Ukraine, United Kingdom, United States

Participant flow

Pre-assignment details

Study comprised of screening, double-blind (DB), open-label (OL) and safety follow-up (FU) periods. The DB period started with an 8-week up-titration phase and lasted until all participants either completed the Week 28 visit or prematurely discontinued the study.

Participants by arm

Arm	Count
Double Blind (DB) Period: Macitentan During the 8-week up-titration phase, participants received macitentan doses orally once daily (QD): 10 mg tablet for 4 weeks followed by 37.5 mg tablet for another 4 weeks prior to reaching the target maintenance phase dose of macitentan 75 mg QD. Participants were to remain on double-blind maintenance treatment until the last participant randomized completed the Week 28 visit. Participants who prematurely discontinued DB study treatment prior to Week 28 but did not withdraw consent were asked to enter post-treatment observation period (PTOP) from DB period last dose until Week 28. Median exposure to DB treatment was 24.50 weeks (minimum: 3.9 weeks; maximum: 160.4 weeks).	64
DB Period: Placebo Participants received placebo matched to macitentan dose levels during the DB treatment period. Participants who prematurely discontinued DB study treatment prior to Week 28 but did not withdraw consent were asked to enter PTOP from DB period last dose until Week 28. Median exposure to DB treatment was 44 weeks (minimum: 4 weeks; maximum: 147.9 weeks).	63
Total	127

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
DB Period: Day 1 up to EODBT	Death	1	0	0	0
DB Period: Day 1 up to EODBT	Other	8	5	0	0
DB Period: Day 1 up to EODBT	Physician Decision	8	1	0	0
DB Period: Day 1 up to EODBT	Study Terminated by Sponsor	41	52	0	0
DB Period: Day 1 up to EODBT	Withdrawal by Subject	5	4	0	0
OL Period:Day 1 Upto End of OL Treatment	Other	0	0	0	1
OL Period:Day 1 Upto End of OL Treatment	Study Terminated by Sponsor	0	0	1	5

Baseline characteristics

Characteristic	Double Blind (DB) Period: Macitentan	DB Period: Placebo	Total
AgeContinuous	64.7 years STANDARD_DEVIATION 11.69	60.3 years STANDARD_DEVIATION 12.84	62.5 years STANDARD_DEVIATION 12.41
Age, Customized Adults (18-64 years)	23 Participants	33 Participants	56 Participants
Age, Customized From 65 to 75 years	32 Participants	26 Participants	58 Participants
Age, Customized Over 75 years	9 Participants	4 Participants	13 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	3 Participants	4 Participants	7 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	59 Participants	58 Participants	117 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants	1 Participants	3 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Asian	18 Participants	26 Participants	44 Participants
Race (NIH/OMB) Black or African American	0 Participants	2 Participants	2 Participants
Race (NIH/OMB) More than one race	0 Participants	1 Participants	1 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Unknown or Not Reported	4 Participants	0 Participants	4 Participants
Race (NIH/OMB) White	42 Participants	34 Participants	76 Participants
Region of Enrollment ARGENTINA	0 Participants	1 Participants	1 Participants
Region of Enrollment AUSTRALIA	1 Participants	1 Participants	2 Participants
Region of Enrollment BULGARIA	1 Participants	2 Participants	3 Participants
Region of Enrollment CHINA	7 Participants	10 Participants	17 Participants
Region of Enrollment CZECH REPUBLIC	3 Participants	1 Participants	4 Participants
Region of Enrollment DENMARK	1 Participants	1 Participants	2 Participants
Region of Enrollment FRANCE	2 Participants	0 Participants	2 Participants
Region of Enrollment GERMANY	7 Participants	4 Participants	11 Participants
Region of Enrollment HUNGARY	1 Participants	1 Participants	2 Participants
Region of Enrollment ISRAEL	1 Participants	0 Participants	1 Participants
Region of Enrollment ITALY	3 Participants	1 Participants	4 Participants
Region of Enrollment JAPAN	5 Participants	9 Participants	14 Participants
Region of Enrollment LITHUANIA	0 Participants	1 Participants	1 Participants
Region of Enrollment MEXICO	2 Participants	2 Participants	4 Participants
Region of Enrollment POLAND	4 Participants	5 Participants	9 Participants
Region of Enrollment PORTUGAL	0 Participants	3 Participants	3 Participants
Region of Enrollment ROMANIA	3 Participants	0 Participants	3 Participants
Region of Enrollment RUSSIAN FEDERATION	5 Participants	0 Participants	5 Participants
Region of Enrollment SAUDI ARABIA	1 Participants	1 Participants	2 Participants
Region of Enrollment SINGAPORE	1 Participants	0 Participants	1 Participants
Region of Enrollment SLOVAKIA	1 Participants	0 Participants	1 Participants
Region of Enrollment SOUTH KOREA	3 Participants	5 Participants	8 Participants
Region of Enrollment SPAIN	1 Participants	1 Participants	2 Participants
Region of Enrollment TAIWAN	1 Participants	1 Participants	2 Participants
Region of Enrollment THAILAND	1 Participants	1 Participants	2 Participants
Region of Enrollment TURKEY	2 Participants	4 Participants	6 Participants
Region of Enrollment UNITED KINGDOM	2 Participants	0 Participants	2 Participants
Region of Enrollment UNITED STATES	5 Participants	8 Participants	13 Participants
Sex: Female, Male Female	37 Participants	42 Participants	79 Participants
Sex: Female, Male Male	27 Participants	21 Participants	48 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	1 / 64	0 / 63	0 / 1	0 / 6
other Total, other adverse events	47 / 64	38 / 63	1 / 1	5 / 6
serious Total, serious adverse events	17 / 64	14 / 63	0 / 1	4 / 6

Outcome results

Primary

Change From Baseline in 6-minute Walk Distance (6MWD) at Week 28

Change from baseline in 6MWD as measured by 6-minute walk test (6MWT) at Week 28 was reported. The purpose of the 6MWT was to quantify exercise tolerance and capacity. This standardized test measured the distance an individual was able to walk over a total of six minutes on a hard, flat surface with no obstacles. The goal was for the individual to walk as far as possible in 6 minutes.

Time frame: Baseline (Day 1), Week 28

Population: Full analysis set (FAS) included all randomized participants assigned to a study intervention and were analyzed according to the intervention they had been assigned to via interactive web response system (IWRS). Here, 'N' (number of participants analyzed) signifies number of participants evaluable for this outcome measure.

Arm	Measure	Value (LEAST_SQUARES_MEAN)	Dispersion
Double Blind (DB) Period: Macitentan	Change From Baseline in 6-minute Walk Distance (6MWD) at Week 28	9.7 Meters	Standard Error 5.81
DB Period: Placebo	Change From Baseline in 6-minute Walk Distance (6MWD) at Week 28	25.8 Meters	Standard Error 5.78

p-value: 0.97495% CI: [-32.34, 0.16]MMRM

Secondary

Change From Baseline to Week 28 in Accelerometer-assessed Proportion of Time Spent in Moderate to Vigorous Physical Activity

Change from baseline to Week 28 in accelerometer-assessed proportion of time spent in moderate to vigorous physical activity were assessed. Daily life physical activity of participant was assessed using accelerometer which was provided to the participant at screening and was worn daily during waking hours up to Week 28. For each scheduled visit, the 14 days prior to the visit were considered as the assessment period for physical activity. To be considered evaluable for a given timepoint, actigraphy variables should have been measured for at least 7 complete days (consecutive or not). A complete day is defined as a record of at least 7 waking hours of data. Proportion of time spent in moderate to vigorous physical activity was the estimated number of minutes spent in moderate or higher physical activity as calculated using the Staudenmayer '15 technique as proportion of the total minutes of algorithmically detected wear time and excluding the minutes that fall within a sleep period.